Loading company…
MAXVAX is a Chengdu biotech developing vaccines and adjuvants, including influenza, rabies and shingles vaccines.
Established in 2016 and based in Chengdu, China, Chengdu Maikekang BioTechnology Co., Ltd., doing business as Maxhealth or MAXVAX, develops vaccines and adjuvants, including new influenza, rabies, rotavirus and shingles vaccines for the elderly. Founder Dr. Dexiang Chen previously worked at Wyeth, Novartis and PATH. In December 2025 the company closed Series D+ funding from Chengdu Science and Technology Venture Capital Group, BIO-TOWN Capital, Shenzhen Capital Real Estate Fund and other investors.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in